When the Precision Medicine Initiative (PMI) was launched in January 2015 as “a bold new research effort to revolutionize how we improve health and treat disease,” according to The White House, it brought challenges to the entire healthcare supply chain.
The U.S. FDA’s website, for example, said, “The vast amount of information generated through next-generation sequencing (NGS) poses novel regulatory issues for FDA.”
